Full Text Journal Articles by
Author Toby M Maher

Advertisement

Find full text journal articles






Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but not Forgotten.

Toby M Maher,

Am J Respir Crit Care Med (American journal of respiratory and critical care medicine)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study.

Joanna C Porter, Thida Win, Kjell Erlandsson, Francesco Fraioli, Alaleh Rashidnasab, Beverley Holman, Balaji Ganeshan, Nicholas J Screaton, Toby M Maher, Raymond Endozo, John Hoath, Robert I Shortman, Elise Emond, Kris Thielemans, Brian F Hutton, Pauline T Lukey, Franklin Aigbirhio, Saif Khan, Manuel Rodriguez-Justo, Ashley M Groves,

Eur Respir J (The European respiratory journal)
[2021, 58(4):]

Cited: 0 times

View full text PDF listing >>



Advertisement

DNA Methylome Alterations Are Associated with Airway Macrophage Differentiation and Phenotype during Lung Fibrosis.

Peter McErlean, Christopher G Bell, Richard J Hewitt, Zabreen Busharat, Patricia P Ogger, Poonam Ghai, Gesa J Albers, Emily Calamita, Shaun Kingston, Philip L Molyneaux, Stephan Beck, Clare M Lloyd, Toby M Maher, Adam J Byrne,

<b>Rationale:</b> Airway macrophages (AMs) are key regulators of the lung environment and are implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal respiratory disease with no cure. However, knowledge about the epigenetics of AMs in IPF is limited. <b>Objectives:</b> To assess the role of epigenetic regulation of AMs ... Read more >>

Am J Respir Crit Care Med (American journal of respiratory and critical care medicine)
[2021, 204(8):954-966]

Cited: 0 times

View full text PDF listing >>



Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World.

Markus Polke, Yasuhiro Kondoh, Marlies Wijsenbeek, Vincent Cottin, Simon L F Walsh, Harold R Collard, Nazia Chaudhuri, Sergey Avdeev, Jürgen Behr, Gregory Calligaro, Tamera J Corte, Kevin Flaherty, Manuela Funke-Chambour, Martin Kolb, Johannes Krisam, Toby M Maher, Maria Molina Molina, Antonio Morais, Catharina C Moor, Julie Morisset, Carlos Pereira, Silvia Quadrelli, Moises Selman, Argyrios Tzouvelekis, Claudia Valenzuela, Carlo Vancheri, Vanesa Vicens-Zygmunt, Julia Wälscher, Wim Wuyts, Elisabeth Bendstrup, Michael Kreuter,

<b>Background:</b> Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe complication associated with a high mortality. However, evidence and guidance on management is sparse. The aim of this international survey was to assess differences in prevention, diagnostic and treatment strategies for AE-IPF in specialised and non-specialised ILD centres worldwide. ... Read more >>

Front Med (Lausanne) (Frontiers in medicine)
[2021, 8:699644]

Cited: 0 times

View full text PDF listing >>



Clinical Utility of Home versus Hospital Spirometry in Fibrotic ILD: Evaluation Following INJUSTIS Interim Analysis.

Fasihul Khan, Lucy Howard, Glenn Hearson, Colin Edwards, Chris Barber, Steve Jones, Andrew M Wilson, Toby M Maher, Gauri Saini, Iain Stewart, Gisli Jenkins,

Ann Am Thorac Soc (Annals of the American Thoracic Society)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT

Andrew M Wilson, Allan B Clark, Anthony Cahn, Edwin R Chilvers, William Fraser, Matthew Hammond, David M Livermore, Toby M Maher, Helen Parfrey, Ann Marie Swart, Susan Stirling, David Thickett, Moira Whyte,

()
[, :]

Cited: 0 times

View full text PDF listing >>



Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis.

Iain D Stewart, Henry Nanji, Grazziela Figueredo, William A Fahy, Toby M Maher, Antje J Ask, Shyam Maharaj, Kjetil Ask, Martin Kolb, Gisli R Jenkins,

Eur Respir J (The European respiratory journal)
[2021, 58(1):]

Cited: 0 times

View full text PDF listing >>



Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?

Toby M Maher,

Ann Am Thorac Soc (Annals of the American Thoracic Society)
[2021, 18(8):1285-1286]

Cited: 0 times

View full text PDF listing >>



Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.

Kerri I Aronson, Sonye K Danoff, Anne-Marie Russell, Christopher J Ryerson, Atsushi Suzuki, Marlies S Wijsenbeek, Sabrina Bajwah, Pauline Bianchi, Tamera J Corte, Joyce S Lee, Kathleen O Lindell, Toby M Maher, Fernando J Martinez, Paula M Meek, Ganesh Raghu, Glenda Rouland, Rick Rudell, Monika M Safford, Jamie S Sheth, Jeffrey J Swigris,

<b>Background:</b> In the past two decades, many advances have been made to our understanding of interstitial lung disease (ILD) and the way we approach its treatment. Despite this, many questions remain unanswered, particularly those related to how the disease and its therapies impact outcomes that are most important to patients. ... Read more >>

Am J Respir Crit Care Med (American journal of respiratory and critical care medicine)
[2021, 204(2):e3-e23]

Cited: 0 times

View full text PDF listing >>



Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells.

Yong Huang, Justin M Oldham, Shwu-Fan Ma, Avraham Unterman, Shu-Yi Liao, Andrew J Barros, Catherine A Bonham, John S Kim, Rekha Vij, Ayodeji Adegunsoye, Mary E Strek, Philip L Molyneaux, Toby M Maher, Jose D Herazo-Maya, Naftali Kaminski, Bethany B Moore, Fernando J Martinez, Imre Noth,

<b>Rationale:</b> Disease activity in idiopathic pulmonary fibrosis (IPF) remains highly variable, poorly understood, and difficult to predict. <b>Objectives:</b> To identify a predictor using short-term longitudinal changes in gene expression that forecasts future FVC decline and to characterize involved pathways and cell types. <b>Methods:</b> Seventy-four patients from COMET (Correlating Outcomes with ... Read more >>

Am J Respir Crit Care Med (American journal of respiratory and critical care medicine)
[2021, 204(2):197-208]

Cited: 0 times

View full text PDF listing >>



Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis.

Michael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, Justin M Oldham, Philip L Molyneaux, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler, Toby M Maher,

<b>Rationale:</b> There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. <b>Objectives:</b> We used pooled data from pirfenidone and IFNγ-1b trials to explore the association between monocyte count and prognosis in patients with IPF. <b>Methods:</b> This retrospective pooled ... Read more >>

Am J Respir Crit Care Med (American journal of respiratory and critical care medicine)
[2021, 204(1):74-81]

Cited: 3 times

View full text PDF listing >>



Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.

Imre Noth, Vincent Cottin, Nazia Chaudhuri, Tamera J Corte, Kerri A Johannson, Marlies Wijsenbeek, Stephane Jouneau, Andreas Michael, Manuel Quaresma, Klaus B Rohr, Anne-Marie Russell, Susanne Stowasser, Toby M Maher, ,

<h4>Background</h4>Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).<h4>Methods</h4>Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label ... Read more >>

Eur Respir J (The European respiratory journal)
[2021, 58(1):]

Cited: 1 time

View full text PDF listing >>



Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era.

Gizal Nakshbandi, Catharina C Moor, Kerri A Johannson, Toby M Maher, Michael Kreuter, Marlies S Wijsenbeek,

<b>The #COVID19 pandemic has led to an increase in the use of eHealth for patients with interstitial lung disease. Healthcare providers worldwide are positive towards further implementation of eHealth for research and clinical practice.</b> https://bit.ly/3h2545M. ... Read more >>

ERJ Open Res (ERJ open research)
[2021, 7(3):]

Cited: 0 times

View full text PDF listing >>



Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.

Toby M Maher, Kevin K Brown, Michael Kreuter, Anand Devaraj, Simon L F Walsh, Lisa H Lancaster, Elizabeth A Belloli, Maria Padilla, Juergen Behr, Rainer-Georg Goeldner, Kay Tetzlaff, Rozsa Schlenker-Herceg, Kevin R Flaherty, ,

The INBUILD trial investigated nintedanib <i>versus</i> placebo in patients with progressive fibrosing interstitial lung diseases (ILDs). We investigated decline in forced vital capacity (FVC) in subgroups based on the inclusion criteria for ILD progression.Subjects had a fibrosing ILD other than idiopathic pulmonary fibrosis and met these criteria for ILD progression ... Read more >>

Eur Respir J (The European respiratory journal)
[2021, :]

Cited: 0 times

View full text PDF listing >>



50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study.

Brenda M Juan Guardela, Jiehuan Sun, Tong Zhang, Bing Xu, Joseph Balnis, Yong Huang, Shwu-Fan Ma, Philip L Molyneaux, Toby M Maher, Imre Noth, Gaetane Michaud, Ariel Jaitovich, Jose D Herazo-Maya,

<h4>Background</h4>COVID-19 has been associated with Interstitial Lung Disease features. The immune transcriptomic overlap between Idiopathic Pulmonary Fibrosis (IPF) and COVID-19 has not been investigated.<h4>Methods</h4>we analyzed blood transcript levels of 50 genes known to predict IPF mortality in three COVID-19 and two IPF cohorts. The Scoring Algorithm of Molecular Subphenotypes (SAMS) ... Read more >>

EBioMedicine (EBioMedicine)
[2021, 69:103439]

Cited: 2 times

View full text PDF listing >>



Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial.

Toby M Maher, Maureen D Mayes, Christian Stock, Margarida Alves,

Following the publication of further analyses of the effects of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial (1), Dr Bredemeier queried whether the occurrence of gastrointestinal adverse events in subjects treated with nintedanib may have reduced the effectiveness of masking and so introduced ... Read more >>

Arthritis Rheumatol (Arthritis & rheumatology (Hoboken, N.J.))
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical utility of home versus hospital spirometry in fibrotic ILD: evaluation following INJUSTIS interim analysis

Fasihul Khan, Lucy Howard, Glenn Hearson, Colin Edwards, Chris Barber, Steve Jones, Andrew Wilson, Toby Maher, Gauri Saini, Iain Stewart, Gisli Jenkins,

The COVID-19 pandemic identified an urgent need to re-evaluate the provision of spirometry for clinical monitoring. Home spirometry offers the opportunity for real-time disease evaluation without risk of nosocomial infection. To determine the utility of home spirometry in interstitial lung disease (ILD), interim data from the ongoing INJUSTIS study was ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.

Nikhil Hirani, Alison C MacKinnon, Lisa Nicol, Paul Ford, Hans Schambye, Anders Pedersen, Ulf J Nilsson, Hakon Leffler, Tariq Sethi, Susan Tantawi, Lise Gravelle, Robert J Slack, Ross Mills, Utsa Karmakar, Duncan Humphries, Fredrik Zetterberg, Lucy Keeling, Lyn Paul, Philip L Molyneaux, Feng Li, Wendy Funston, Ian A Forrest, A John Simpson, Michael A Gibbons, Toby M Maher,

Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3.A randomised, double-blind, multicentre, placebo-controlled, phase 1/2a study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics ... Read more >>

Eur Respir J (The European respiratory journal)
[2021, 57(5):]

Cited: 9 times

View full text PDF listing >>



Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis.

Athina Trachalaki, Eliza Tsitoura, Semeli Mastrodimou, Rachele Invernizzi, Eirini Vasarmidi, Eleni Bibaki, Nikolaos Tzanakis, Philip L Molyneaux, Toby M Maher, Katerina Antoniou,

Fibrotic Interstitial lung diseases (ILDs) are complex disorders of variable clinical behaviour. The majority of them cause significant morbidity, whilst Idiopathic Pulmonary Fibrosis (IPF) is recognised as the most relentless. NLRP3, AIM2, and NLRC4 inflammasomes are multiprotein complexes driving IL-1β release; a proinflammatory and profibrotic cytokine. Several pathogenetic factors associated ... Read more >>

Front Immunol (Frontiers in immunology)
[2021, 12:661811]

Cited: 1 time

View full text PDF listing >>



Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?

Meena Kalluri, Fabrizio Luppi, Ada Vancheri, Carlo Vancheri, Elisabetta Balestro, Francesco Varone, Nesrin Mogulkoc, Giulia Cacopardo, Elena Bargagli, Elizabeth Renzoni, Sebastiano Torrisi, Mariarosaria Calvello, Alessandro Libra, Mauro Pavone, Francesco Bonella, Vincent Cottin, Claudia Valenzuela, Marlies Wijsenbeek, Elisabeth Bendstrup, ,

Patient-reported outcome measures (PROMs), tools to assess patient self-report of health status, are now increasingly used in research, care and policymaking. While there are two well-developed disease-specific PROMs for interstitial lung diseases (ILD) and idiopathic pulmonary fibrosis (IPF), many unmet and urgent needs remain. In December 2019, 64 international ILD ... Read more >>

Eur Respir Rev (European respiratory review : an official journal of the European Respiratory Society)
[2021, 30(160):]

Cited: 0 times

View full text PDF listing >>



Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study.

Claire M Nolan, Suhani Patel, Ruth E Barker, Jessica A Walsh, Oliver Polgar, Matthew Maddocks, Peter M George, Elisabetta A Renzoni, Athol U Wells, Philip L Molyneaux, Vasilis Kouranos, Felix Chua, Toby M Maher, William D-C Man,

<h4>Objectives</h4>To assess the acceptability of neuromuscular electrical stimulation (NMES) of the quadriceps muscles in people with idiopathic pulmonary fibrosis (IPF) and to identify whether a future definitive trial is feasible.<h4>Design</h4>A randomised, parallel, two-group, participant and assessor-blinded, placebo-controlled feasibility trial with embedded qualitative interviews.<h4>Setting</h4>Outpatient department, Royal Brompton and Harefield Hospitals.<h4>Participants</h4>Twenty-two people ... Read more >>

BMJ Open (BMJ open)
[2021, 11(6):e048808]

Cited: 0 times

View full text PDF listing >>



Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.

Ryan S Dhindsa, Johan Mattsson, Abhishek Nag, Quanli Wang, Louise V Wain, Richard Allen, Eleanor M Wigmore, Kristina Ibanez, Dimitrios Vitsios, Sri V V Deevi, Sebastian Wasilewski, Maria Karlsson, Glenda Lassi, Henric Olsson, Daniel Muthas, Susan Monkley, Alex Mackay, Lynne Murray, Simon Young, Carolina Haefliger, , Toby M Maher, Maria G Belvisi, Gisli Jenkins, Philip L Molyneaux, Adam Platt, Slavé Petrovski,

Idiopathic pulmonary fibrosis (IPF) is a fatal disorder characterised by progressive, destructive lung scarring. Despite substantial progress, the genetic determinants of this disease remain incompletely defined. Using whole genome and whole exome sequencing data from 752 individuals with sporadic IPF and 119,055 UK Biobank controls, we performed a variant-level exome-wide ... Read more >>

Commun Biol (Communications biology)
[2021, 4(1):392]

Cited: 1 time

View full text PDF listing >>



Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.

Toby M Maher, Maureen D Mayes, Michael Kreuter, Elizabeth R Volkmann, Martin Aringer, Ivan Castellvi, Maurizio Cutolo, Christian Stock, Nils Schoof, Margarida Alves, Ganesh Raghu, ,

<h4>Objective</h4>In the SENSCIS trial in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categorical changes in FVC and other measures of ... Read more >>

Arthritis Rheumatol (Arthritis & rheumatology (Hoboken, N.J.))
[2021, 73(4):671-676]

Cited: 2 times

View full text PDF listing >>



Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations.

Olivia C Leavy, Shwu-Fan Ma, Philip L Molyneaux, Toby M Maher, Justin M Oldham, Carlos Flores, Imre Noth, R Gisli Jenkins, Frank Dudbridge, Louise V Wain, Richard J Allen,

Am J Respir Crit Care Med (American journal of respiratory and critical care medicine)
[2021, 203(6):775-778]

Cited: 2 times

View full text PDF listing >>



Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.

Toby M Maher, Ulrich Costabel, Marilyn K Glassberg, Yasuhiro Kondoh, Takashi Ogura, Mary Beth Scholand, David Kardatzke, Monet Howard, Julie Olsson, Margaret Neighbors, Paula Belloni, Jeffrey J Swigris,

This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF).Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%-100% predicted and diffusing capacity for carbon monoxide ... Read more >>

Eur Respir J (The European respiratory journal)
[2021, 57(2):]

Cited: 2 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0557 s